Biotech Showcase™ 2016: Interview: LSE stakes claim as source of patient capital for biotechs

February 26, 2016
Biotech and medtech companies looking to tap into the deep pools of US capital should consider a London listing. London Stock Exchange's Chris Mayo tells Mike Ward, global director of content for Informa's pharma insights products, that non-US companies can get access to US investors while not having to endure expensive reporting requirements. Moreover, he says, as many US biotechs and medtech businesses have listed in London as UK firms have listed in the US as they sought to attract what Mayo describes as patient capital. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: BC Platforms making genomics data meaningful
Biotech Showcase™ 2016: Interview: BC Platforms making genomics data meaningful

BC Platforms CEO Tero Silvola explains to Mike Ward, global director of content for Informa's pharma insigh...

Next Video
Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions
Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions

Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director o...